CANY
TCRR

Caxton Associates (New York)’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Caxton Associates (New York)’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,784
Closed -$106K – 760
2021
Q4 		$106K Buy
+22,784
New +$142K 0.01% 523

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Caxton Associates (New York)'s TCRR Position: Q1 2022 in Review

Caxton Associates (New York) sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 22,784 shares — an estimated $106K sold.

Caxton Associates (New York) first reported a position in TCRR in Q4 2021 and held it in 1 quarter. The position peaked at $106K in Q4 2021. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • Caxton Associates (New York) reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 22,784 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $106K.
  • Caxton Associates (New York) first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s TCR2 Therapeutics Inc. Common Stock position peaked at $106K in Q4 2021.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.